Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer

@inproceedings{Marshall2015SelectiveAI,
  title={Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer},
  author={Derek C. Marshall and Susan K. Lyman and Scott A McCauley and Maria Kovalenko and Rhyannon Spangler and Chian Liu and Michael Lee and Christopher B. O’Sullivan and Vivian Barry-Hamilton and Haben Ghermazien and Amanda Mikels-Vigdal and Carlos A. Cuello Garcia and Brett Jorgensen and Arleene C. Velayo and Ruth Wang and Joanne I. Adamkewicz and Victoria Smith},
  booktitle={PloS one},
  year={2015}
}
Expression of matrix metalloproteinase 9 (MMP9) is elevated in a variety of inflammatory and oncology indications, including ulcerative colitis and colorectal cancer. MMP9 is a downstream effector and an upstream mediator of pathways involved in growth and inflammation, and has long been viewed as a promising therapeutic target. However, previous efforts to target matrix metalloproteinases (MMPs), including MMP9, have utilized broad-spectrum or semi-selective inhibitors. While some of these… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

Similar Papers

Loading similar papers…